Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Pfizer”

A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in AdultsCompleted
NCT06890416Phase 3Updated Nov 6, 2025
Sponsor: Pfizer
Respiratory Syncytial Virus (RSV)
United States, Puerto Rico
Estimated Vaccine Effectiveness and Durability of Pfizer/BioNTech 2024-2025 COVID-19 VaccineTerminated
NCT06703190N/AUpdated Nov 6, 2025
Sponsor: Pfizer
COVID-19
United States
A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in ChinaCompleted
NCT03909971Phase 2Updated Nov 5, 2025
Sponsor: Pfizer
Carcinoma, Non-Small-Cell Lung
China
BrECADD Therapy in Stage 2 B-IV Hodgkin LymphomaRecruiting
NCT07002216Phase 2Updated Nov 3, 2025
Sponsor: University of Miami
Hodgkin Lymphoma · Advanced Hodgkin Lymphoma
United States
Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)Completed
NCT04029480Phase 3Updated Oct 31, 2025
Sponsor: Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
United States, Belgium, Canada, Colombia, Costa Rica +17 more
Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid TumoursCompleted
NCT03620643Phase 2Updated Oct 30, 2025
Sponsor: Royal Marsden NHS Foundation Trust
Lobular Breast Carcinoma · Gastric Cancer · Triple Negative Breast Cancer · CDH1 Gene Mutation
United Kingdom
A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)Completed
NCT02677896Phase 3Updated Oct 24, 2025
Sponsor: Astellas Pharma Global Development, Inc.
Metastatic Hormone Sensitive Prostate Cancer
United States, Argentina, Australia, Belgium, Canada +19 more
Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder CancerActive Not Recruiting
NCT05241340Phase 2Updated Oct 24, 2025
Sponsor: The Methodist Hospital Research Institute
Urothelial Carcinoma Bladder
United States
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain InvolvementTerminated
NCT04543188Phase 1Updated Oct 23, 2025
Sponsor: Pfizer
Malignant Melanoma · Carcinoma, Non-Small-Cell Lung · Brain Neoplasms, Primary · Brain Neoplasms
United States, Canada, Israel
Role of Immune System in Obesity-related Inflammation and Cardiometabolic RiskActive Not Recruiting
NCT01104220NAUpdated Oct 23, 2025
Sponsor: Washington University School of Medicine
Non-alcoholic Fatty Liver Disease · Metabolic Syndrome · Metabolically Abnormal Obesity · Metabolically Normal Obesity
United States
Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast CancerRecruiting
NCT05508906Phase 1Updated Oct 22, 2025
Sponsor: Olema Pharmaceuticals, Inc.
Metastatic Breast Cancer · ER-positive Breast Cancer · HER2-negative Breast Cancer · Breast Cancer
United States, Australia
A Study to Learn How Different Amounts of the Study Medicine Called PF-07314470 Are Tolerated and Act in the Body in Healthy AdultsTerminated
NCT06821750Phase 1Updated Oct 22, 2025
Sponsor: Pfizer
Healthy
United States
A Study to Understand the Long-term Safety and Effects of an Experimental Gene Therapy for Duchenne Muscular Dystrophy.Terminated
NCT05689164Phase 3Updated Oct 21, 2025
Sponsor: Pfizer
Duchenne Muscular Dystrophy
United States
Study of Fordadistrogene Movaparvovec in Early Stage Duchenne Muscular DystrophyTerminated
NCT05429372Phase 2Updated Oct 21, 2025
Sponsor: Pfizer
Muscular Dystrophy, Duchenne
United States, Australia
A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIVCompleted
NCT05794191N/AUpdated Oct 20, 2025
Sponsor: Pfizer
HIV · Pneumonia · Infections, Pneumococcal
United States
Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]-PF-07304814 in Healthy ParticipantsCompleted
NCT05050682Phase 1Updated Oct 20, 2025
Sponsor: Pfizer
Healthy
United States
A Study to Compare Health Care Costs Between Apixaban and Low Molecular Weight Heparin in Patients With Venous Thromboembolism and CancerCompleted
NCT05643885N/AUpdated Oct 20, 2025
Sponsor: Pfizer
Thromboembolism
United States
Effectiveness of Treatment With Tofacitinib in Patients With Psoriatic Arthritis in Routine Clinical PracticeCompleted
NCT04517669N/AUpdated Oct 14, 2025
Sponsor: Pfizer
Psoriatic Arthritis
Belgium, Denmark, Finland, France, Israel +3 more
A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast CancerTerminated
NCT03901469Phase 2Updated Oct 7, 2025
Sponsor: Zenith Epigenetics
Triple Negative Breast Cancer
United States, Belgium, China, Spain
ERd Combination Treatment in Newly Diagnosed Multiple MyelomaRecruiting
NCT06997081Phase 2Updated Oct 7, 2025
Sponsor: University of Miami
Multiple Myeloma
United States
Non Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and Refractory Multiple Myeloma Treated With Elranatamab Under the Actual Use.Active Not Recruiting
NCT06479954N/AUpdated Oct 2, 2025
Sponsor: Pfizer
Relapsed and Refractory Multiple Myeloma (RRMM)
Japan
Ngenla Subcutaneous Injection Special InvestigationActive Not Recruiting
NCT05602766N/AUpdated Oct 2, 2025
Sponsor: Pfizer
Growth Hormone Deficiency Without Epiphyseal Closure
Japan
A Study to Learn How Different Amounts and Forms of the Study Medicine Called PF-06414300 Act in Healthy AdultsCompleted
NCT06659250Phase 1Updated Oct 1, 2025
Sponsor: Pfizer
Healthy Participants
United States
Prevention of Very Preterm Delivery by Testing for and Treatment of Bacterial VaginosisCompleted
NCT00642980Phase 4Updated Oct 1, 2025
Sponsor: University Hospital, Lille
Pregnancy
France
A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy IndividualsCompleted
NCT05472038Phase 2, Phase 3Updated Oct 1, 2025
Sponsor: BioNTech SE
SARS-CoV-2 Infection · COVID-19
United States

Previous page Next page